Opportunity Information: Apply for PAR 16 093
Apply for PAR 16 093
- The HHS-NIH11 in the environment, health sector is offering a public funding opportunity titled "Improvement of Animal Models for Stem Cell-Based Regenerative Medicine (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.113, 93.121, 93.351, 93.855, 93.856.
- This funding opportunity was created on Feb 09, 2016 and posted on Feb 09, 2016.
- Applicants must submit their applications by May 07, 2019. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For profit organizations other than small businesses, Small businesses, Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The NIH funding opportunity titled "Improvement of Animal Models for Stem Cell-Based Regenerative Medicine (R01)" (Funding Opportunity Number PAR-16-093) supports investigator-initiated Research Project Grant (R01) applications that aim to strengthen and expand the animal-model foundation needed for developing stem cell-based regenerative therapies. The core purpose is to improve how well animal systems predict human outcomes by advancing the characterization of animal stem cells and by improving existing, or creating entirely new, animal models that better represent human disease conditions. In practical terms, the program is built around the idea that regenerative medicine will move faster and more safely into the clinic when researchers have model systems that more accurately mirror human stem cell biology, disease progression, and therapeutic response.
A major emphasis of the initiative is comparative research that directly evaluates similarities and differences between animal and human stem cells. Projects in this area might include careful side-by-side analyses of stem cell identity, potency, differentiation behavior, engraftment characteristics, and functional outcomes across species. The goal is to generate evidence that helps the field choose the most predictive and informative animal model for a given therapeutic question, rather than relying on tradition or convenience. This comparative angle is meant to reduce translational surprises, where a treatment appears promising in one species but fails in humans due to underlying biological mismatches.
The FOA also encourages development of new tools and technologies that improve stem cell characterization and transplantation in animal systems. This can include better methods to identify and track transplanted cells, assess their survival and integration, measure their functional contribution to tissue repair, or monitor safety concerns such as abnormal growth, ectopic tissue formation, or immune complications. Technology development is positioned as a key enabler: if researchers can measure the right things more accurately and noninvasively, or standardize assays for cell identity and function, then animal studies can provide clearer answers about mechanisms and likely clinical performance.
A third focus is the improvement of animal disease models specifically for stem cell-based therapeutic applications. This goes beyond creating general disease phenotypes and instead stresses models that are suitable for testing regenerative strategies in a way that resembles clinical reality. That can include refining how diseases are induced or progress, incorporating relevant comorbidities, designing endpoints that reflect meaningful functional recovery, and building models that better capture human immune responses, tissue architecture, or injury microenvironments. The intent is to create or upgrade models so that they can support rigorous preclinical evaluation of stem cell therapies, including dosing, delivery routes, durability of effect, and safety.
In terms of administrative details, this opportunity is a discretionary NIH grant program under the U.S. Department of Health and Human Services (Agency listed as HHS-NIH11) using the R01 funding instrument. It spans health-related research areas reflected in CFDA numbers 93.113, 93.121, 93.351, 93.855, and 93.856. Eligibility is broad and includes many organization types: state, county, and local governments; special district governments; independent school districts; public and state-controlled universities; private institutions of higher education; federally recognized tribal governments and other tribal organizations; public housing authorities/Indian housing authorities; nonprofit organizations with or without 501(c)(3) status; for-profit organizations other than small businesses; small businesses; and other applicants as described in the NIH eligibility language. The opportunity was posted and created on February 9, 2016, with the listed closing date of May 7, 2019. The award ceiling and expected number of awards are not specified in the provided source information, which typically means applicants should rely on the standard NIH R01 budgeting rules and the specific institute or center guidance tied to the FOA.
Overall, PAR-16-093 is aimed at making animal studies more informative, more reproducible, and more directly applicable to human regenerative medicine by improving the biological relevance of model systems, strengthening the toolkit for evaluating stem cell products and transplants, and generating the comparative data needed to pick the right species and model design for a given therapeutic goal.
FAQs: Improvement of Animal Models for Stem Cell-Based Regenerative Medicine (R01) - PAR-16-093
What is the title and funding opportunity number for this NIH grant?
The opportunity is titled "Improvement of Animal Models for Stem Cell-Based Regenerative Medicine (R01)" and the Funding Opportunity Number (FOA) is PAR-16-093.
What is the main purpose of PAR-16-093?
The purpose is to strengthen and expand the animal-model foundation needed to develop stem cell-based regenerative therapies. A central goal is improving how well animal systems predict human outcomes by advancing characterization of animal stem cells and by improving existing or creating new animal models that better represent human disease conditions and therapeutic responses.
What funding mechanism does this opportunity use?
This program uses the NIH Research Project Grant mechanism (R01) and supports investigator-initiated R01 applications.
Which federal agency is offering this funding opportunity?
The funding opportunity is offered under the U.S. Department of Health and Human Services (HHS) through the National Institutes of Health (NIH), with the agency listed as HHS-NIH11.
What kinds of research projects does the FOA prioritize?
Based on the provided description, the FOA emphasizes three broad categories: (1) comparative research evaluating animal versus human stem cells, (2) development of tools and technologies for stem cell characterization and transplantation in animals, and (3) improvement of animal disease models specifically designed for stem cell-based therapeutic testing that better reflects clinical reality.
What is meant by "comparative research" in this FOA?
Comparative research refers to studies that directly evaluate similarities and differences between animal and human stem cells. The intent is to generate evidence that helps researchers choose the most predictive animal model for a specific therapeutic question, rather than relying on tradition or convenience.
What types of stem cell features may be compared across animal and human systems?
The FOA description highlights side-by-side analyses that may include stem cell identity, potency, differentiation behavior, engraftment characteristics, and functional outcomes across species.
Why does the FOA emphasize improving the predictive value of animal models?
The goal is to reduce "translational surprises," where a therapy appears promising in an animal species but fails in humans due to biological mismatches. More predictive models are meant to help regenerative medicine move faster and more safely into clinical testing.
What kinds of tools and technologies are encouraged under this FOA?
The FOA encourages new tools and technologies that improve stem cell characterization and transplantation studies in animals. Examples described include methods to identify and track transplanted cells, assess survival and integration, measure functional contribution to tissue repair, and monitor safety concerns such as abnormal growth, ectopic tissue formation, or immune complications. It also points to the value of more accurate, noninvasive measurements and standardized assays for cell identity and function.
How does this FOA define improvements to animal disease models?
The focus is on models suitable for testing stem cell-based regenerative strategies in a way that resembles clinical reality. This goes beyond creating general disease phenotypes and includes refining disease induction or progression, incorporating relevant comorbidities, designing endpoints that reflect meaningful functional recovery, and improving how models capture human immune responses, tissue architecture, or injury microenvironments.
Does the FOA support creating entirely new animal models, or only refining existing ones?
It supports both. The description explicitly includes improving existing animal models as well as creating entirely new animal models that better represent human disease conditions and therapeutic response.
What kinds of preclinical testing considerations are highlighted for improved models?
The description indicates that improved models should enable rigorous preclinical evaluation of stem cell therapies, including dosing, delivery routes, durability of effect, and safety.
What is the intended impact of better measurement and standardization in animal studies?
As described, better measurement (including potentially noninvasive approaches) and standardized assays can help animal studies provide clearer answers about mechanisms and likely clinical performance, thereby improving the informativeness, reproducibility, and translational applicability of preclinical work.
Who is eligible to apply for PAR-16-093?
Eligibility is described as broad and includes: state, county, and local governments; special district governments; independent school districts; public and state-controlled universities; private institutions of higher education; federally recognized tribal governments and other tribal organizations; public housing authorities/Indian housing authorities; nonprofit organizations with or without 501(c)(3) status; for-profit organizations other than small businesses; small businesses; and other applicants as described in NIH eligibility language.
Are small businesses eligible to apply?
Yes. The provided eligibility list explicitly includes small businesses.
Are for-profit organizations eligible to apply?
Yes. The provided eligibility list includes for-profit organizations other than small businesses, and it also includes small businesses.
Are tribal governments and tribal organizations eligible?
Yes. The eligibility list includes federally recognized tribal governments and other tribal organizations.
Are nonprofits required to have 501(c)(3) status to apply?
No. The eligibility list includes nonprofit organizations with or without 501(c)(3) status.
What CFDA numbers are associated with this opportunity?
The opportunity references the following CFDA numbers: 93.113, 93.121, 93.351, 93.855, and 93.856.
When was this funding opportunity posted and created?
The opportunity was posted and created on February 9, 2016.
What is the listed closing date for this FOA?
The listed closing date is May 7, 2019.
Is the award ceiling provided in the information given?
No. The award ceiling is not specified in the provided source information.
Is the expected number of awards provided in the information given?
No. The expected number of awards is not specified in the provided source information.
What budgeting guidance is implied when award amounts are not specified?
The description notes that when award ceilings are not specified, applicants typically rely on standard NIH R01 budgeting rules and any institute or center guidance tied to the FOA.
Is this opportunity intended to support regenerative medicine broadly, or specifically stem cell-based regenerative therapies?
It is specifically focused on stem cell-based regenerative therapies, with an emphasis on animal models and tools that improve prediction of human outcomes and support rigorous preclinical testing.
What is the overarching goal of PAR-16-093 in terms of translation to the clinic?
The overarching goal is to make animal studies more informative, more reproducible, and more directly applicable to human regenerative medicine by improving the biological relevance of model systems, strengthening evaluation tools for stem cell products and transplants, and producing comparative data that helps select the most predictive species and model design for a given therapeutic goal.
Browse more opportunities from the same category: Environment, Health
Next opportunity: Supplemental and Alternative Crops Competitive Grants Program
Previous opportunity: Service Area Competition – Additional Area (SAC-AA) – St. Paul (Island), Alaska
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 16 093
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 16 093) also looked into and applied for these:
| Funding Opportunity |
|---|
| Improvement of Animal Models for Stem Cell-Based Regenerative Medicine (R21) Apply for PAR 16 094 Funding Number: PAR 16 094 Agency: HHS-NIH11 Category: Environment, Health Funding Amount: $200,000 |
| Countermeasures Against Chemical Threats (CounterACT): Optimization of Therapeutic Lead Compounds (U01) Apply for PAR 16 128 Funding Number: PAR 16 128 Agency: HHS-NIH11 Category: Environment, Health Funding Amount: Case Dependent |
| Countermeasures Against Chemical Threats (CounterACT): Identification of Therapeutic Lead Compounds (U01) Apply for PAR 16 129 Funding Number: PAR 16 129 Agency: HHS-NIH11 Category: Environment, Health Funding Amount: $300,000 |
| Mechanism for Time-Sensitive Opportunity in Environmental Health Sciences (R21) Apply for RFA ES 16 005 Funding Number: RFA ES 16 005 Agency: HHS-NIH11 Category: Environment, Health Funding Amount: $200,000 |
| Collaborative Activities to Expedite Environmental Health Science Research, Translation, and Community Engagement Across EHS Core Centers (Admin Supp) Apply for PA 16 327 Funding Number: PA 16 327 Agency: HHS-NIH11 Category: Environment, Health Funding Amount: $100,000 |
| Countermeasures Against Chemical Threats (CounterACT) Research Centers of Excellence (U54) Apply for PAR 16 329 Funding Number: PAR 16 329 Agency: HHS-NIH11 Category: Environment, Health Funding Amount: $2,500,000 |
| Countermeasures Against Chemical Threats (CounterACT): Optimization of Therapeutic Lead Compounds (U01) Apply for PAR 16 331 Funding Number: PAR 16 331 Agency: HHS-NIH11 Category: Environment, Health Funding Amount: Case Dependent |
| Countermeasures Against Chemical Threats (CounterACT): Identification of Therapeutic Lead Compounds (U01) Apply for PAR 16 330 Funding Number: PAR 16 330 Agency: HHS-NIH11 Category: Environment, Health Funding Amount: $300,000 |
| NIH Big Data to Knowledge (BD2K) Enhancing Diversity in Biomedical Data Science (R25) Apply for RFA MD 16 002 Funding Number: RFA MD 16 002 Agency: Department of Health and Human Services, National Institutes of Health Category: Environment, Health Funding Amount: $300,000 |
| Collaborative Activities to Expedite Environmental Health Science Research, Translation, and Community Engagement Across EHS Core Centers (Admin Supp) Apply for PA 17 317 Funding Number: PA 17 317 Agency: Department of Health and Human Services, National Institutes of Health Category: Environment, Health Funding Amount: $100,000 |
| Immuno-Oncology Translation Network (IOTN): Cancer Immunoprevention Research Projects (U01) Apply for RFA CA 17 046 Funding Number: RFA CA 17 046 Agency: Department of Health and Human Services, National Institutes of Health Category: Environment, Health Funding Amount: $500,000 |
| Collaborative Activities to Expedite Environmental Health Science Research, Translation, and Community Engagement Across EHS Core Centers (Admin Supp - Clinical Trial Not Allowed) Apply for PA 18 770 Funding Number: PA 18 770 Agency: Department of Health and Human Services, National Institutes of Health Category: Environment, Health Funding Amount: $100,000 |
| Functional RNA Modifications Environment and Disease (FRAMED) (R21 Clinical Trial Not Allowed) Apply for RFA ES 19 002 Funding Number: RFA ES 19 002 Agency: Department of Health and Human Services, National Institutes of Health Category: Environment, Health Funding Amount: $150,000 |
| Functional RNA Modifications Environment and Disease (FRAMED) (R01 Clinical Trial Not Allowed) Apply for RFA ES 19 001 Funding Number: RFA ES 19 001 Agency: Department of Health and Human Services, National Institutes of Health Category: Environment, Health Funding Amount: $250,000 |
| NIEHS Research Intensive Short Courses and Educational Opportunities (NIEHS RISE) (R25 Clinical Trial Not Allowed) Apply for RFA ES 20 015 Funding Number: RFA ES 20 015 Agency: Department of Health and Human Services, National Institutes of Health Category: Environment, Health Funding Amount: $200,000 |
| Alumni Engagement Innovation Fund 2022 Apply for PAS JOR FY22 003 Funding Number: PAS JOR FY22 003 Agency: Department of State, U.S. Mission to Jordan Category: Environment, Health Funding Amount: $40,000 |
| SBIR E-learning for HAZMAT and Emergency Response (R43/R44) Apply for RFA ES 16 006 Funding Number: RFA ES 16 006 Agency: National Institutes of Health Category: Environment, Health Funding Amount: Case Dependent |
| The Preconception Exposure Window and Health of the Offspring (R01) Apply for RFA ES 16 007 Funding Number: RFA ES 16 007 Agency: National Institutes of Health Category: Environment, Health Funding Amount: $300,000 |
| Transition to Independent Environmental Health Research (TIEHR) Career Transition Award (K01) Apply for PAR 16 360 Funding Number: PAR 16 360 Agency: National Institutes of Health Category: Environment, Health Funding Amount: Case Dependent |
| Revolutionizing Innovative, Visionary Environmental health Research (RIVER) (R35) Apply for RFA ES 16 008 Funding Number: RFA ES 16 008 Agency: National Institutes of Health Category: Environment, Health Funding Amount: $750,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 16 093", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.